TRCT
ORMP icon

Tower Research Capital (TRC)’s Oramed Pharmaceuticals ORMP Stock Holding History

Tower Research Capital (TRC)’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-693
Closed -$1.98K – 5433
2025
Q4 		$1.98K Buy
+693
New +$1.79K ﹤0.01% 4604
2025
Q2 		– Sell
-649
Closed -$1.39K – 5487
2025
Q1 		$1.39K Sell
649
-1,996
-75% -$4.61K ﹤0.01% 4720
2024
Q4 		$6.4K Sell
2,645
-5,352
-67% -$12.7K ﹤0.01% 4177
2024
Q3 		$19.5K Sell
7,997
-4,392
-35% -$10.7K ﹤0.01% 3248
2024
Q2 		$31.8K Buy
12,389
+9,727
+365% +$23.1K ﹤0.01% 3441
2024
Q1 		$7.77K Buy
2,662
+2,076
+354% +$5.8K ﹤0.01% 4142
2023
Q4 		$1.35K Sell
586
-1,656
-74% -$3.54K ﹤0.01% 5394
2023
Q3 		$5.85K Sell
2,242
-7,102
-76% -$22.4K ﹤0.01% 4677
2023
Q2 		$33.5K Buy
9,344
+9,310
+27,382% +$29.8K ﹤0.01% 2926
2023
Q1 		$0 Sell
34
-1,272
-97% -$4.04K ﹤0.01% 6158
2022
Q4 		$16K Buy
1,306
+1,106
+553% +$8.6K ﹤0.01% 3364
2022
Q3 		$1K Sell
200
-1,647
-89% -$13.3K ﹤0.01% 5818
2022
Q2 		$9K Sell
1,847
-20,342
-92% -$109K ﹤0.01% 4576
2022
Q1 		$192K Buy
22,189
+18,755
+546% +$192K ﹤0.01% 1751
2021
Q4 		$49K Buy
3,434
+2,738
+393% +$57.2K ﹤0.01% 2775
2021
Q3 		$15K Sell
696
-2,397
-77% -$40.8K ﹤0.01% 3991
2021
Q2 		$41K Sell
3,093
-1,920
-38% -$22K ﹤0.01% 3188
2021
Q1 		$51K Buy
5,013
+4,786
+2,108% +$39.3K ﹤0.01% 3112
2020
Q4 		$1K Buy
+227
New +$739 ﹤0.01% 5022
2020
Q3 		– Sell
-4,104
Closed -$14K – 5020
2020
Q2 		$14K Buy
4,104
+380
+10% +$1.27K ﹤0.01% 3874
2020
Q1 		$11K Buy
3,724
+2,865
+334% +$12.6K ﹤0.01% 1986
2019
Q4 		$4K Sell
859
-17,632
-95% -$66.1K ﹤0.01% 2802
2019
Q3 		$59K Buy
18,491
+16,997
+1,138% +$56.6K ﹤0.01% 1676
2019
Q2 		$5K Sell
1,494
-12
-0.8% -$42 ﹤0.01% 2949
2019
Q1 		$5K Buy
+1,506
New +$4.98K ﹤0.01% 3079
2018
Q4 		– Sell
-861
Closed -$4K – 4204
2018
Q3 		$4K Buy
+861
New +$4.47K ﹤0.01% 3208
2018
Q2 		– Sell
-281
Closed -$2K – 3942
2018
Q1 		$2K Buy
281
+150
+115% +$1.16K ﹤0.01% 2960
2017
Q4 		$1K Sell
131
-262
-67% -$2.5K ﹤0.01% 3354
2017
Q3 		$4K Buy
393
+210
+115% +$1.81K ﹤0.01% 3398
2017
Q2 		$1K Buy
+183
New +$1.38K ﹤0.01% 2511
2017
Q1 		– Sell
-526
Closed -$3K – 3676
2016
Q4 		$3K Sell
526
-758
-59% -$4.94K ﹤0.01% 3272
2016
Q3 		$10K Buy
1,284
+884
+221% +$6.87K ﹤0.01% 2067
2016
Q2 		$3K Buy
400
+49
+14% +$417 ﹤0.01% 3724
2016
Q1 		$2K Buy
351
+86
+32% +$576 ﹤0.01% 3415
2015
Q4 		$2K Sell
265
-365
-58% -$2.77K ﹤0.01% 3779
2015
Q3 		$4K Buy
+630
New +$3.96K ﹤0.01% 2963
2015
Q1 		– Sell
-405
Closed -$2K – 4780
2014
Q4 		$2K Sell
405
-35
-8% -$230 ﹤0.01% 3361
2014
Q3 		$4K Sell
440
-1,400
-76% -$12.4K ﹤0.01% 3445
2014
Q2 		$17K Sell
1,840
-3,519
-66% -$35.9K ﹤0.01% 1936
2014
Q1 		$63K Buy
5,359
+5,339
+26,695% +$90.1K 0.01% 936
2013
Q4 		$0 Sell
20
-2,313
-99% -$17.8K ﹤0.01% 4809
2013
Q3 		$14K Buy
2,333
+1,233
+112% +$8.77K ﹤0.01% 2960
2013
Q2 		$9K Buy
+1,100
New +$9.06K ﹤0.01% 2458

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.37B AUM
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $102M AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Tower Research Capital (TRC)'s ORMP Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of Oramed Pharmaceuticals (ORMP) in Q1 2026, closing a stake of 693 shares — an estimated $1.98K sold.

Tower Research Capital (TRC) first reported a position in ORMP in Q2 2013 and held it in 43 quarters. The position peaked at $192K in Q1 2022. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining Oramed Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 693 Oramed Pharmaceuticals shares in Q1 2026, an estimated $1.98K.
  • Tower Research Capital (TRC) first reported a position in Oramed Pharmaceuticals in Q2 2013 and held it in 43 quarters.
  • Tower Research Capital (TRC)'s Oramed Pharmaceuticals position peaked at $192K in Q1 2022.
  • 64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.